Ismaya Wangsa T, Efthyani Alida, Tjandrawinata Raymond R, Rachmawati Heni
Dexa Laboratories of Biomolecular Sciences, JABABEKA II Industrial Estate, Cikarang, 17550, Indonesia.
School of Pharmacy, Institut Teknologi Bandung, Bandung, 40132, Indonesia.
J Biochem Mol Toxicol. 2017 Nov;31(11). doi: 10.1002/jbt.21958. Epub 2017 Jul 12.
Light subunit of mushroom tyrosinase (LSMT) is a protein of unknown function from mushroom Agaricus bisporus that has been demonstrated to permeate through rat intestine ex vivo. Thus, it can be absorbed in the intestine, thereby holding a promise as a drug carrier for oral administration, similar to HA-33 protein from botulinum, one of the closest structural homologs of LSMT. However, the safety of LSMT should be ensured prior to its use. Here, we described biological response of LSMT upon weekly intraperitoneal administration of 50 μg/day to the Balb/c mice for 12 weeks. Motoric and behavior profiles, as well as the index of main organs (liver, spleen, lung, heart, and kidney), and body weight, were not significantly changed as compared with the control group. Also, no IgG was detected in the serum. The results suggest that LSMT is safe for further development.
蘑菇酪氨酸酶轻亚基(LSMT)是来自双孢蘑菇的一种功能未知的蛋白质,已证实在离体条件下可透过大鼠肠道。因此,它能够在肠道中被吸收,从而有望成为一种口服给药的药物载体,类似于肉毒杆菌的HA - 33蛋白,它是LSMT最相近的结构同源物之一。然而,在使用LSMT之前应确保其安全性。在此,我们描述了每周腹腔注射50μg/天的LSMT,持续12周给予Balb/c小鼠后的生物学反应。与对照组相比,运动和行为特征以及主要器官(肝脏、脾脏、肺、心脏和肾脏)的指标和体重均无显著变化。此外,血清中未检测到IgG。结果表明,LSMT进一步开发是安全的。